Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO–ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease: A Retrospective Single-Center Study. Issue 1 (14th September 2021)

• Record Type: Journal Article
• Authors: D'Arcangelo, Giulia; Abi Nader, Elie; Charbit-Henrion, Fabienne; Talbotec, Cécile; Goulet, Olivier; Ruemmele, Frank M.; Pigneur, Bénédicte
• Is Part Of: Journal of pediatric gastroenterology and nutrition. Volume 74:Issue 1(2022)
• Page Start: 79
• Page End: 84
• Publication Date: 2021-09-14
• Subjects: biologics -- inflammatory bowel disease -- pediatrics -- surgery; Children -- Nutrition -- Periodicals; Pediatric gastroenterology -- Periodicals; Infants -- Nutrition -- Periodicals; Nutrition disorders in children -- Periodicals; Child Nutrition -- Periodicals; Digestive System -- growth & development -- Periodicals; Gastrointestinal Diseases -- Periodicals; Infant Nutrition -- Periodicals; Nutrition Disorders -- Periodicals; Child; 618.923
• DOI: 10.1097/MPG.0000000000003301
• Languages: English
• ISSNs: 0277-2116

Abstract

Abstract : Supplemental Digital Content is available in the text ABSTRACT: Objectives: The first ECCO-ESPGHAN guidelines for the medical management of pediatric Crohn disease (CD) were published in 2014. Whether their implementation, and the consequent increased use of an upfront anti-tumor necrosis factor therapy, have changed the course of the disease has not been investigated yet. We aimed at comparing the evolution of pediatric CD patients diagnosed and treated before and after 2014. Methods: Single-center retrospective study including all children diagnosed with CD from January 2010 to December 2018. Patients diagnosed between 2010 and 2014 (group 1) were compared to those diagnosed after 2014 (group 2). For each patient, at baseline and every 6-month, number of relapses, the occurrence of complication, therapy received and biological parameters were noted, as well as any endoscopic or radiologic evaluation. Results: One hundred and fifty-four patients were included in the analysis, 78 (51%) diagnosed after 2014. The cumulative probability of a relapse-free and surgery-free course was significantly higher for patients treated according to the guidelines (log rank hazard ratio [HR] = 1, 818, P = 0.003 and HR = 3, 15, 95% confidence interval, P = 0.04, respectively). Mucosal healing rate was significantly higher among patients of group 2 at 1 and 2 years ( P = 0.04 and P = 0.05, respectively), while no significant difference was observed for transmural healing rates, as well as for the risk of complications. Conclusions: The implementation of the 2014 CD guidelines appears to have a significant impact on disease outcomes, with a significantly lower risk for relapse and surgery, while no effect could be observed on the risk of developing complications.